-
Product Insights
Hemorrhagic Shock - Drugs In Development, 2024
Empower your strategies with our Hemorrhagic Shock – Drugs In Development, 2024 report and make more profitable business decisions. Hemorrhagic shock is hypovolemic shock from blood loss. Traumatic injury is by far the most common cause of hemorrhagic shock. Hypovolemic shock is a form of shock caused by severe hypovolemia (insufficient blood volume or extracellular fluid in the body). It could be the result of severe dehydration through a variety of mechanisms or blood loss. Hypovolemic shock is a medical emergency;...
-
Product Insights
Myocardial Ischemia - Drugs In Development, 2024
Empower your strategies with our Myocardial Ischemia – Drugs In Development, 2024 report and make more profitable business decisions. Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris); neck or jaw pain; shoulder or arm pain; clammy skin; shortness of breath; and nausea and vomiting. Myocardial ischemia can be caused by conditions such as...
-
Product Insights
Pulmonary Embolism - Drugs In Development, 2024
Empower your strategies with our Pulmonary Embolism – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat, and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics. The Pulmonary Embolism drugs in development market research...
-
Product Insights
Intermittent Claudication - Drugs In Development, 2024
Empower your strategies with our Intermittent Claudication – Drugs In Development, 2024 report and make more profitable business decisions. Intermittent claudication is caused by a narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs, and sores or wounds on the lower limb that heal slowly or poorly. Risk factors include smoking, high cholesterol, high...
-
Product Insights
Raynauds Disease - Drugs In Development, 2024
Empower your strategies with our Raynauds Disease – Drugs In Development, 2024 report and make more profitable business decisions. Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history, and smoking. Symptoms include fingers, toes, ears, or nose turning white and then blue. Treatment includes vasodilators, alpha blockers, and calcium channel blockers. The Raynauds Disease drugs in development market research report provide...
-
Product Insights
Thromboembolic Disease - Drugs In Development, 2024
Empower your strategies with our Thromboembolic Disease – Drugs In Development, 2024 report and make more profitable business decisions. Thromboembolism is a condition in which a a thrombus (blood clot) detaches and blocks the blood vessel (embolizes). Venous thromboembolism can lead to two types of conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk factors that contribute to VTE are injury to vein, infection, immobilization, high estrogen, smoking, obesity, age, chronic illness, and blood clotting conditions. Signs and symptoms include...
-
Product Insights
Aneurysm - Drugs In Development, 2024
Empower your strategies with our Aneurysm – Drugs In Development, 2024 report and make more profitable business decisions. An aneurysm is a weak or expanded bulge in the wall of an artery. The different types are abdominal aortic aneurysm (AAA), cerebral aneurysms, thoracic aortic aneurysm, and carotid, popliteal, mesenteric, and splenic aneurisms. Atherosclerosis, family history of aneurysm, high blood pressure, and injury to the aorta can be the causative parameters. Symptoms include lightheadedness; tachycardia; sudden, severe pain in the head, chest...
-
Product Insights
Behcet Disease - Drugs In Development, 2024
Empower your strategies with our Behcet Disease – Drugs In Development, 2024 report and make more profitable business decisions. Behcet disease, sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals. More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious...
-
Product Insights
Endocarditis - Drugs In Development, 2024
Empower your strategies with our Endocarditis – Drugs In Development, 2024 report and make more profitable business decisions. Endocarditis is a rare, life-threatening inflammatory condition that occurs when the inner lining of the heart's chambers and valves become infected. It is usually caused by bacterial infection, and rarely by fungus. Symptoms include high temperature, chills, night sweats, headaches, shortness of breath, cough, fatigue, muscle and joint pain, heart murmur, and pale skin. Blood culture tests, CBC, CRP, ESR, and echocardiogram are...
-
Product Insights
Thromboangiitis obliterans (Buerger disease) - Drugs In Development, 2024
Empower your strategies with our Thromboangiitis obliterans (Buerger disease) – Drugs In Development, 2024 report and make more profitable business decisions. Thromboangiitis obliterans (TAO), also called Buerger disease, is a rare nonatherosclerotic inflammatory disorder in which blood vessels of the hands and feet become blocked. It has a strong association with smoking. Symptoms of Buerger’s disease are hand or foot pain (burning or tingling feeling), sores on toes or fingers, change in skin color or texture, and cold hands or feet....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.